2. Academic Validation
  3. Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome

Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome

  • Bioorg Med Chem Lett. 2011 Jan 1;21(1):58-61. doi: 10.1016/j.bmcl.2010.11.080.
David D Manning 1,  Christopher L Cioffi,  Alexander Usyatinsky,  Kevin Fitzpatrick,  Liaqat Masih,  Cheng Guo,  Zhenjun Zhang,  Sok Hui Choo,  M Inthikhab Sikkander,  Kristen N Ryan,  Jennifer Naginskaya,  Carla Hassler,  Svetlana Dobritsa,  Jonathan D Wierschke,  William G Earley,  Amy S Butler,  Catherine A Brady,  Nicholas M Barnes,  Marlene L Cohen,  Peter R Guzzo
Affiliations

Affiliation

  • 1 Discovery R&D AMRI, 26 Corporate Circle, PO Box 15098, Albany, NY 12212-5098, United States. David.Manning@amriglobal.com
PMID: 21146988 DOI: 10.1016/j.bmcl.2010.11.080
Abstract

Serotonin type 3 (5-HT(3)) receptor partial agonists are being targeted as potential new drugs for the treatment of irritable bowel syndrome (IBS). Two new chemical series bearing indazole and indole cores have exhibited nanomolar binding affinity for the h5-HT(3)A receptor. A range of partial agonist activities in HEK cells heterologously expressing the h5-HT(3)A receptor were measured for the indazole series. Excellent 5-HT(3) receptor selectivity, favorable in vitro metabolic stability and CYP inhibition properties, and good oral in vivo potency in the murine von Bezold-Jarisch reflex model is exemplified thereby indicating the series to have potential utility as improved IBS agents.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z